Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMEA NASDAQ:FATE NASDAQ:KZR NASDAQ:PYXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.93-2.8%$1.79$1.29▼$13.07$114.80M-0.131.29 million shs467,757 shsFATEFate Therapeutics$0.97-4.8%$1.10$0.66▼$4.20$111.18M2.211.98 million shs1.20 million shsKZRKezar Life Sciences$3.97-0.4%$4.16$3.62▼$9.18$28.73M0.6138,071 shs2,630 shsPYXSPyxis Oncology$1.84-1.3%$1.27$0.83▼$5.39$115.05M1.14572,233 shs591,071 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion+7.61%+8.20%+20.00%-16.10%-73.81%FATEFate Therapeutics+2.00%+5.15%+8.94%-20.00%-73.71%KZRKezar Life Sciences-0.50%+4.19%+2.05%-13.29%-31.14%PYXSPyxis Oncology-0.53%+15.53%+78.85%+55.00%-48.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.93-2.8%$1.79$1.29▼$13.07$114.80M-0.131.29 million shs467,757 shsFATEFate Therapeutics$0.97-4.8%$1.10$0.66▼$4.20$111.18M2.211.98 million shs1.20 million shsKZRKezar Life Sciences$3.97-0.4%$4.16$3.62▼$9.18$28.73M0.6138,071 shs2,630 shsPYXSPyxis Oncology$1.84-1.3%$1.27$0.83▼$5.39$115.05M1.14572,233 shs591,071 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion+7.61%+8.20%+20.00%-16.10%-73.81%FATEFate Therapeutics+2.00%+5.15%+8.94%-20.00%-73.71%KZRKezar Life Sciences-0.50%+4.19%+2.05%-13.29%-31.14%PYXSPyxis Oncology-0.53%+15.53%+78.85%+55.00%-48.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion 3.17Buy$14.80668.83% UpsideFATEFate Therapeutics 2.14Hold$3.30239.86% UpsideKZRKezar Life Sciences 2.33Hold$9.00126.99% UpsidePYXSPyxis Oncology 2.67Moderate Buy$7.75322.34% UpsideCurrent Analyst Ratings BreakdownLatest KZR, PYXS, FATE, and BMEA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025PYXSPyxis OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.009/3/2025PYXSPyxis OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/28/2025BMEABiomea FusionJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/28/2025BMEABiomea FusionJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/18/2025PYXSPyxis OncologyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/13/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$4.00 ➝ $2.508/11/2025BMEABiomea FusionCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $7.008/6/2025BMEABiomea FusionScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Outperform$30.00 ➝ $10.008/6/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.008/5/2025BMEABiomea FusionOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$1.42 per shareN/AFATEFate Therapeutics$8.47M13.22N/AN/A$2.80 per share0.35KZRKezar Life Sciences$7M4.15N/AN/A$16.02 per share0.25PYXSPyxis Oncology$16.15M7.05N/AN/A$2.03 per share0.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$138.43M-$3.03N/AN/AN/AN/A-243.95%-140.74%11/4/2025 (Estimated)FATEFate Therapeutics-$186.26M-$1.45N/AN/AN/A-2,025.05%-50.95%-36.76%11/11/2025 (Estimated)KZRKezar Life Sciences-$83.74M-$9.69N/AN/AN/AN/A-63.51%-52.13%11/11/2025 (Estimated)PYXSPyxis Oncology-$77.33M-$1.60N/AN/AN/AN/A-68.56%-52.14%11/11/2025 (Estimated)Latest KZR, PYXS, FATE, and BMEA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PYXSPyxis Oncology-$0.36-$0.30+$0.06-$0.30N/A$2.82 million8/13/2025Q2 2025KZRKezar Life Sciences-$2.15-$1.87+$0.28-$1.87N/AN/A8/12/2025Q2 2025FATEFate Therapeutics-$0.35-$0.29+$0.06-$0.29$1.16 million$1.91 million8/5/2025Q2 2025BMEABiomea Fusion-$0.59-$0.51+$0.08-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A3.683.68FATEFate TherapeuticsN/A8.048.04KZRKezar Life Sciences0.037.297.29PYXSPyxis OncologyN/A5.655.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%FATEFate Therapeutics97.54%KZRKezar Life Sciences67.90%PYXSPyxis Oncology39.09%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion18.42%FATEFate Therapeutics5.51%KZRKezar Life Sciences10.40%PYXSPyxis Oncology10.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion5059.51 million48.55 millionOptionableFATEFate Therapeutics550115.33 million108.98 millionOptionableKZRKezar Life Sciences607.32 million6.56 millionNot OptionablePYXSPyxis Oncology6062.02 million55.44 millionOptionableKZR, PYXS, FATE, and BMEA HeadlinesRecent News About These CompaniesPyxis Oncology, Inc. $PYXS Holdings Lowered by American Century Companies Inc.September 9 at 3:16 AM | marketbeat.comInvesting in Oncology: 3 Cancer Stocks With Promising PipelinesSeptember 8, 2025 | zacks.comPyxis Oncology (NASDAQ:PYXS) Raised to Strong-Buy at GuggenheimSeptember 8, 2025 | marketbeat.comGuggenheim Initiates Coverage of Pyxis Oncology (PYXS) with Buy RecommendationSeptember 5, 2025 | msn.comPyxis Oncology initiated with a Buy at GuggenheimSeptember 3, 2025 | msn.comAnalysts Set Pyxis Oncology, Inc. (NASDAQ:PYXS) Price Target at $8.67September 2, 2025 | americanbankingnews.comPyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 1, 2025 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street ZenAugust 26, 2025 | marketbeat.comHC Wainwright Predicts Increased Earnings for Pyxis OncologyAugust 23, 2025 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Raised to Hold at Zacks ResearchAugust 22, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS)August 21, 2025 | marketbeat.comPyxis Oncology to Participate in September Investor and Industry ConferencesAugust 21, 2025 | globenewswire.comWilliam Blair Forecasts Pyxis Oncology Q1 EarningsAugust 19, 2025 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPSAugust 18, 2025 | marketbeat.comPyxis Oncology reports Q2 EPS (30c), consensus (35c)August 14, 2025 | msn.comPyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comWe Think Pyxis Oncology (NASDAQ:PYXS) Needs To Drive Business Growth CarefullyAugust 2, 2025 | finance.yahoo.comPyxis Oncology Inc News (PYXS) - Investing.comJuly 8, 2025 | investing.comPyxis Oncology Chief Financial, Operating Officer Pamela Connealy Retires >PYXSJuly 3, 2025 | marketwatch.comPyxis Oncology Appoints New Principal Financial OfficerJuly 3, 2025 | tipranks.comPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKZR, PYXS, FATE, and BMEA Company DescriptionsBiomea Fusion NASDAQ:BMEA$1.92 -0.06 (-2.78%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Fate Therapeutics NASDAQ:FATE$0.97 -0.05 (-4.80%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Kezar Life Sciences NASDAQ:KZR$3.96 -0.02 (-0.43%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Pyxis Oncology NASDAQ:PYXS$1.84 -0.03 (-1.34%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
